Cancilico

What Cancilico does

Cancilico GmbH is a Dresden-based health-tech company founded in 2023 as a spin-off from TU Dresden University of Technology and University Hospital Dresden. The company develops MyeloAID, an AI-powered computer vision platform that automates the morphological differentiation of bone marrow smears, performing automated cell counting and classification to produce detailed, reproducible myelograms in minutes. The software is hardware-agnostic, integrating with existing microscopes or whole-slide scanners, and is delivered via a cloud platform that returns structured bone marrow differentials and PDF reports.

The underlying technology rests on proprietary deep learning models trained on a curated, multimodal dataset of healthy and diseased bone marrow sourced from leading European hematology centres and labeled by more than ten senior morphology experts. Cancilico also extends these capabilities into Pharma Services, providing pharmaceutical companies with digital biomarker development, predictive disease and subgroup modeling, therapy response biomarkers, and clinical trial support. Named pharma partners include Novartis and Servier.

Cancilico operates two revenue streams: SaaS-based MyeloAID software licensing, currently sold as Research Use Only pending FDA and CE-IVDR clearance, and collaborative Pharma Services engagements with pharmaceutical companies. Go-to-market is enterprise field sales targeting hematology labs, hospitals, and reference labs, supplemented by an embedded distribution channel through integration with Smart In Media's PathoZoom digital pathology platform. The company has 1-10 employees and is led by CEO Markus Badstübner, with senior leadership covering clinical, AI, engineering, product, and regulatory functions.

Name

Cancilico

Legal name

Cancilico GmbH

Website

https://cancilico.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Cancilico GmbH develops MyeloAID, an AI-powered computer vision platform that automates bone marrow cell classification and counting for hematology labs, hospitals, and pharmaceutical partners, and offers collaborative pharma services for digital biomarker development.

Ownership category

akta.pro rank

Product category

AI Diagnostic Software for Hematology (Digital Pathology)

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• AI diagnostic software
• Bone marrow analysis
• Hematology imaging
• Digital pathology
• Computer vision diagnostics

Headquarters

HQ city

Dresden

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. MyeloAID Software Licenses: SaaS-based AI diagnostic software for bone marrow analysis, currently available for research use only (RUO) with plans for IVDR and FDA clearance to enable clinical diagnostic use. Subscription or usage-based licensing model implied by cloud platform delivery.
2. Pharma Services: Collaborative research projects with pharmaceutical companies including predictive disease modeling, therapy response biomarkers, translational research, and clinical trial support using AI models and digital biomarkers.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Cancilico develops and sells MyeloAID, an AI- and computer-vision-powered diagnostic software that automates the morphological differentiation of bone marrow smears by counting and classifying cells to produce detailed myelograms in minutes. The software is delivered as a cloud platform that works with existing microscopes or whole-slide scanners without requiring new six-figure hardware, and is currently available for Research Use Only while the company pursues FDA and CE-IVDR clearance. The company also offers collaborative Pharma Services that apply its proprietary bone marrow, histology, and lymphatic tissue dataset to digital biomarker development, patient stratification, and clinical trial support.

Product overview

Cancilico offers a single unified product called MyeloAID — an AI-powered bone marrow morphology analysis platform — supplemented by Pharma Services that provide collaborative research partnerships with pharmaceutical companies. MyeloAID automates cell counting and classification for bone marrow differential analysis, while Pharma Services extends the company's AI capabilities to drug development, clinical trials, and biomarker discovery using the same underlying technology and proprietary dataset.

Differentiator

Problem solved

Functional benefit

Brands

• MyeloAID: AI-assisted diagnostic software for bone marrow morphology that automates cell counting and classification, producing detailed myelograms in minutes for hematology labs.

Products and services

• MyeloAID AI-assisted diagnostic software that automates the morphological differentiation of bone marrow smears by counting and classifying cells and producing a detailed, reproducible bone marrow differential in minutes; works with existing microscopes or whole-slide scanners. Sold to hematology labs, hospitals, and reference labs; currently Research Use Only pending FDA and CE-IVDR clearance.
• Pharma Services Collaborative research and AI services for pharmaceutical companies including digital biomarker development, predictive disease modeling, therapy response biomarkers, patient stratification, and clinical trial support in hematology, leveraging Cancilico's proprietary multimodal bone marrow, histology, and lymphatic tissue dataset.

Quantifiable outcome

• Reduces time for bone marrow differential analysis
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core, major and minor.

• Smart In MediacoreTechnology or IntegrationPlatform integration partner. MyeloAID Research Use Only version is integrated with Smart In Media's PathoZoom digital pathology platform, enabling broader market access.
• EKFZ for Digital HealthcoreStrategic or Co-development PartnerResearch partner affiliated with TU Dresden's Else Kröner Fresenius Center for Digital Health. Represents academic collaboration and validation of AI diagnostic technology.
• NovartismajorStrategic or Co-development PartnerPharmaceutical collaboration partner for digital biomarker development in hematology. Cancilico runs collaborative projects with pharmaceutical companies for predictive disease modeling and therapy response biomarkers.
• ServiermajorStrategic or Co-development PartnerPharmaceutical collaboration partner for digital biomarker development in hematology. Projects focus on disease entity prediction, patient stratification, and clinical trial support.
• SEMECOminorOthersListed as a trusted partner on Cancilico's website. Nature of partnership not further specified.
• BioViewminorOthersListed as a trusted partner on Cancilico's website. Nature of partnership not further specified.
• biosaxonyminorOthersSaxon biotech cluster network partner. Listed as a trusted partner on Cancilico's website.
• Silicon SaxonyminorOthersSaxon technology cluster network partner. Listed as a trusted partner on Cancilico's website.

Scale indicators2 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Owkin: AI biotech company applying machine learning to pathology images and clinical data for biomarker discovery and pharma services. Comparable on the pharma-services and AI-on-pathology axis.
• Aiforia: AI-powered image analysis platform for pathology, including hematopathology applications. Comparable as a clinical AI image analysis vendor serving pathology and research labs.
• Scopio Labs: AI-powered digital microscopy company with full-field bone marrow aspirate analysis capabilities. Directly comparable as a competitor building AI-driven cell morphology solutions for hematology labs.
• PathAI: US-based AI pathology company developing deep learning models for diagnostic pathology across multiple tissue types. Comparable as a competitor in AI-driven image-based diagnostic support for pathology and hematology applications.
• Paige: AI pathology company with FDA-authorized products for prostate and other cancer diagnostics. Comparable as an AI diagnostics platform targeting clinical pathology use cases with regulatory clearances.
• Ibex Medical Analytics: Israel-based AI pathology company with deployed clinical-grade diagnostic AI for tissue biopsy analysis. Closely comparable as an AI diagnostics vendor serving hospital and reference lab pathology workflows.
• Mindpeak: Hamburg-based AI pathology company building deep learning tools for routine pathology diagnostics. Closely comparable as a German/European AI pathology competitor pursuing clinical-grade image analysis.

Broad incumbents

• Proscia: Digital pathology software company offering enterprise platform and AI applications for pathology workflows. Comparable as a broader incumbent in the digital pathology software stack where Cancilico's MyeloAID could integrate or compete.
• CellaVision: Swedish company providing automated digital microscopy systems for blood cell morphology, including hematology lab workflows. Comparable as an established incumbent in automated hematology cell analysis adjacent to bone marrow morphology.

Regional players

• Smart In Media: Digital pathology platform provider (PathoZoom) that has integrated Cancilico's MyeloAID RUO version. Comparable as an adjacent European digital pathology platform and ecosystem partner/distributor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cancilico

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancilico